DPP4 inhibitors, such as saxagliptin, alogliptin, sitagliptin, vildagliptin, and linagliptin, are used in the treatment of type-2 diabetes mellitus (T2DM). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.